Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease

摘要

Background: Studies have demonstrated the benefit of dose optimisation in the setting of secondary loss of response to infliximab in inflammatory bowel disease.